| Metric | FY2025 | FY2024 |
|---|---|---|
| Administrative Expenses | $3.7M-10.2% | $4.2M |
| Research and Development Expenses | $3.5M+0.9% | $3.4M |
| Stock Based Compensation | $2.2M+105.7% | $1.1M |
| Franchise Tax Expense | $200K | — |
| Series F-1 Warrant Issuance Expenses | $539K | — |
| Series G Warrant Issuance Expenses | $970K | — |
| Series H Warrant Issuance Expenses | $264K | — |
| Loss from Operations | -$9.8M+3.2% | -$10.2M |
| Interest and Dividend Income | -$225K+35.9% | -$352K |
| Gain on Sales of Marketable Securities | -$2K-123.0% | -$976 |
| Unrealized Gain on Marketable Securities | -$39K-5663.2% | -$671 |
| Impairment on Equity Investment | $1.5M | — |
| Change in fair value of Derivatives Liabilities | -$983K-353.4% | $388K |
| Change in fair value of Contingent Consideration | $1.5M | — |
| Change in fair value of Warrant Liabilities | $4.4M | — |
| Loss on issuance of Series F-1 Convertible Preferred Stock | $3.7M | — |
| Loss on issuance of Series G Convertible Preferred Stock | $5.1M | — |
| Casualty Loss/(Gain) | -$100K | — |
| Total Other (Income) Expenses | $1.8M-86.5% | $13.2M |
| Loss Before Income Taxes | -$11.6M+50.2% | -$23.4M |
| Net Loss | -$11.6M+50.2% | -$23.4M |
| Preferred Stock Dividends | $3.4M-11.7% | $3.8M |
| Net Loss Attributable to Common Stockholders | -$15.0M+44.8% | -$27.2M |
| Basic net loss per common share | -$8.66+99.2% | -$1080.87 |
| Diluted net loss per common share | -$8.66+99.2% | -$1080.87 |
| Weighted average basic common stock outstanding | $1.7M+6784.3% | $25K |
| Weighted average diluted common stock outstanding | $1.7M+6784.3% | $25K |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.